Literature DB >> 24370642

Macrophages in multiple myeloma.

Domenico Ribatti1, Michele Moschetta2, Angelo Vacca3.   

Abstract

Tumor associated macrophages (TAMs) are a rich source of pro-angiogenic cytokines and growth factors, and a relationship between the TAMs content, the rate of tumor growth and the extent of vascularization has been shown in several tumors. In this article, we have summarized the literature and our data concerning the involvement of TAMs in angiogenesis occurring in multiple myeloma. Finally, therapeutic aspects concerning the potential role of molecules which inhibit macrophage recruitment in the tumor side are also discussed.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Anti-angiogenesis; Inflammation; Macrophages; Multiple myeloma

Mesh:

Substances:

Year:  2013        PMID: 24370642     DOI: 10.1016/j.imlet.2013.12.010

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  12 in total

1.  Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.

Authors:  Lai Sum Leoh; Yoon Kyung Kim; Pierre V Candelaria; Otoniel Martínez-Maza; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  J Immunol       Date:  2018-04-13       Impact factor: 5.422

Review 2.  Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

Authors:  Fotis Asimakopoulos; Chelsea Hope; Michael G Johnson; Adam Pagenkopf; Kimberly Gromek; Bradley Nagel
Journal:  J Leukoc Biol       Date:  2017-03-02       Impact factor: 4.962

3.  Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.

Authors:  Shyam K Bandari; Anurag Purushothaman; Vishnu C Ramani; Garrett J Brinkley; Darshan S Chandrashekar; Sooryanarayana Varambally; James A Mobley; Yi Zhang; Elizabeth E Brown; Israel Vlodavsky; Ralph D Sanderson
Journal:  Matrix Biol       Date:  2017-09-06       Impact factor: 11.583

Review 4.  Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells.

Authors:  Calogero Vetro; Alessandra Romano; Flavia Ancora; Francesco Coppolino; Maria V Brundo; Salvatore A Raccuia; Fabrizio Puglisi; Daniele Tibullo; Piera La Cava; Cesarina Giallongo; Nunziatina L Parrinello
Journal:  Front Oncol       Date:  2015-05-21       Impact factor: 6.244

5.  Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss.

Authors:  Naamit Deshet-Unger; Sahar Hiram-Bab; Yasmin Haim-Ohana; Moshe Mittelman; Yankel Gabet; Drorit Neumann
Journal:  Sci Rep       Date:  2016-08-02       Impact factor: 4.379

Review 6.  Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

Authors:  Niels W C J van de Donk; Maarten L Janmaat; Tuna Mutis; Jeroen J Lammerts van Bueren; Tahamtan Ahmadi; A Kate Sasser; Henk M Lokhorst; Paul W H I Parren
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

Review 7.  Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.

Authors:  Massimo Giuliani; Bassam Janji; Guy Berchem
Journal:  Oncotarget       Date:  2017-04-04

8.  Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo.

Authors:  Khatora S Opperman; Kate Vandyke; Kimberley C Clark; Elizabeth A Coulter; Duncan R Hewett; Krzysztof M Mrozik; Nisha Schwarz; Andreas Evdokiou; Peter I Croucher; Peter J Psaltis; Jacqueline E Noll; Andrew Cw Zannettino
Journal:  Neoplasia       Date:  2019-06-24       Impact factor: 5.715

Review 9.  Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma.

Authors:  Dawn Swan; Mark Gurney; Janusz Krawczyk; Aideen E Ryan; Michael O'Dwyer
Journal:  Hemasphere       Date:  2020-04-03

10.  Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.

Authors:  Marije B Overdijk; Sandra Verploegen; Marijn Bögels; Marjolein van Egmond; Jeroen J Lammerts van Bueren; Tuna Mutis; Richard W J Groen; Esther Breij; Anton C M Martens; Wim K Bleeker; Paul W H I Parren
Journal:  MAbs       Date:  2015       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.